Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were impacted by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, is accused of acquiring shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Financial Implications - Bain Capital reportedly gained over $120 million from the shares acquired during the October Offering due to the artificially depressed price [3]. - Cerevel's January 18, 2024, Proxy statement allegedly misled investors about the nature and timing of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - Genmab A/S plans to submit a supplemental Biologics License Application (sBLA) for subcutaneous epcoritamab in combination with rituximab and lenalidomide for treating adult patients with relapsed or refractory follicular lymphoma in the first half of 2025 [1][3] Company Announcement - The sBLA submission is based on positive topline results from the Phase 3 EPCORE FL-1 trial, which showed that epcoritamab plus rituximab (R) met one of its dual primary endpoints of overall response rate (ORR) with a p-value of less than 0.0001 [2][7] - The safety profile of the combination therapy was consistent with known safety profiles of the individual components, and no new safety signals were observed [2][3] About Follicular Lymphoma (FL) - Follicular lymphoma is a slow-growing form of non-Hodgkin's lymphoma, accounting for 20-30% of all cases, with approximately 15,000 new cases diagnosed annually in the U.S. [4] - It is considered incurable with current standard therapies, and patients often experience shorter remission periods with each relapse [4] About the EPCORE FL-1 Trial - The EPCORE FL-1 trial is a Phase 3 open-label interventional study evaluating the safety and efficacy of epcoritamab plus rituximab and lenalidomide versus rituximab alone in patients with relapsed/refractory follicular lymphoma [5] About Epcoritamab - Epcoritamab is an IgG1-bispecific antibody developed using Genmab's DuoBody technology, designed to target CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20+ cells [6][7] - It is currently approved by the FDA as a monotherapy for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy [3][7] Collaboration and Future Plans - Genmab is co-developing epcoritamab with AbbVie, sharing commercial responsibilities in the U.S. and Japan, and both companies are pursuing additional international regulatory approvals for the investigational indication [8][9] - Genmab and AbbVie are also evaluating epcoritamab in various hematologic malignancies across multiple ongoing Phase 3 trials [9]

Core Insights - Allergan Aesthetics, an AbbVie company, is launching "The Confidence Project" to empower women entrepreneurs and close the Confidence Gap [1][4][5] - The program invites business owners to apply for grants and mentorship opportunities, with applications open until May 9, 2025 [1][5] Program Details - The Confidence Project aims to support 250 women entrepreneurs this year, providing them with access to an intensive "Boostcamp" program that includes skill-building, mentorship, and networking [4][5] - Participants will have the opportunity to pitch their businesses for a chance to receive one of 20 grants worth $20,000 each [4][5] Financial Commitment - Since 2023, BOTOX® Cosmetic has allocated $1 million in grant funding to over 40 founders [4] - The initiative is part of a broader goal to empower 50,000 entrepreneurs by 2030 [7] Partnerships - The program is in partnership with Hello Alice, an online platform that assists businesses in launching and growing [4][5] - The collaboration aims to foster long-term growth and leadership among women in business [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Cerevel Therapeutics Holdings, Inc. regarding a class action lawsuit related to alleged misleading statements and omissions during a secondary stock offering and subsequent merger with AbbVie Inc. [1] Group 1: Allegations and Details - The lawsuit claims that Cerevel's October 16, 2023 secondary stock offering documents omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, which artificially deflated Cerevel's stock price until the merger announcement [4] - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [4] - Cerevel's January 18, 2024 Proxy statement is accused of misleading investors regarding the nature and timing of AbbVie's interest in the company [4] Group 2: Class Action Participation - Shareholders who purchased shares of Cerevel during the class period from October 11, 2023, to August 1, 2024, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for June 3, 2025 [3][5] - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's status [5] Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [6]

Core Insights - Foghorn Therapeutics Inc. has elected Neil Gallagher, M.D., Ph.D., and Stuart Duty to its Board of Directors, enhancing its leadership team with experienced professionals in biotechnology and finance [1][2]. Company Overview - Foghorn Therapeutics is a clinical-stage biotechnology company focused on developing a new class of medicines that correct abnormal gene expression to treat serious diseases, particularly in oncology [1][5]. - The company utilizes its proprietary Gene Traffic Control® platform to identify and validate drug targets within the chromatin regulatory system [5]. Leadership Experience - Dr. Neil Gallagher has over 20 years of experience in drug development across various therapeutic areas, including oncology, and currently serves as President and Head of Research and Development at Syndax Pharmaceuticals [3]. - Stuart Duty brings over 30 years of experience in finance and investment banking within the biotechnology sector, having held senior roles at Guggenheim Securities and other firms [4]. Strategic Goals - The addition of Gallagher and Duty to the Board is expected to leverage their strategic insights to advance Foghorn's pipeline, which aims to develop selective therapies for challenging cancer targets [2][4]. - Dr. Gallagher expressed confidence in Foghorn's potential to address unmet medical needs and change treatment paradigms for multiple cancer types [2].

Core Viewpoint - The article discusses a class action lawsuit against Cerevel Therapeutics Holdings, Inc. related to alleged misleading statements and omissions regarding AbbVie's acquisition interest, which impacted the stock price during a secondary offering [1][2]. Group 1: Allegations and Impact - Cerevel's October 16, 2023 secondary stock offering documents allegedly omitted material facts about AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share, leading to an artificially deflated stock price until the merger announcement [2]. - Bain Capital, Cerevel's controlling shareholder, reportedly acquired shares at the depressed price while possessing nonpublic information about AbbVie's acquisition interest, resulting in a windfall of over $120 million when AbbVie agreed to acquire Cerevel for $45 per share on December 6, 2023 [2]. - The January 18, 2024 Proxy statement from Cerevel allegedly misled investors regarding the nature and timing of AbbVie's interest in the company [2]. Group 2: Class Action Details - The class period for the lawsuit includes individuals who sold or disposed of Cerevel stock from October 11, 2023, to August 1, 2024, and those who held shares as of January 8, 2024, entitled to vote on the merger [1]. - The deadline for shareholders to register for the class action is June 3, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [4].

Company Overview - REGENXBIO Inc. is a biotechnology company focused on gene therapy with a mission to improve lives through its curative potential [3] - The company has been a pioneer in AAV gene therapy since its founding in 2009 [3] - REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for Duchenne, RGX-121 for MPS II, and RGX-111 for MPS I, in partnership with Nippon Shinyaku [3] - The company is also collaborating with AbbVie on surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy [3] - Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA® [3] Upcoming Events - REGENXBIO will host a conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for Q1 2025 and recent operational highlights [1] - Listeners can register for the webcast and analysts can participate in the Q&A session through provided links [2] - A replay of the webcast will be available on the company's investor website approximately two hours after the call [2]

Group 1 - The Dividend Aristocrats will underperform compared to the S&P 500 in April after three consecutive months of outperformance [1] - Year-to-date through March, the ProShares S&P 500 Dividend Aristocrat ETF (NOBL) increased by 3.11% [1]

Core Viewpoint - A class action securities lawsuit has been filed against Cerevel Therapeutics Holdings, Inc. due to alleged securities fraud affecting investors during a specific time frame [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who sold or held shares of Cerevel from October 11, 2023, to August 1, 2024, and were affected by the alleged fraud [2]. - The complaint alleges that Cerevel's October 16, 2023, secondary stock offering omitted critical information regarding AbbVie's interest in acquiring Cerevel at a significantly higher price than the offering price of $22.81 per share [3]. - Bain Capital, Cerevel's controlling shareholder, allegedly acquired shares at an artificially low price while possessing nonpublic information about AbbVie's acquisition interest, leading to a substantial profit when AbbVie announced the acquisition at $45 per share [3]. Group 2: Financial Implications - Bain Capital reportedly received over $120 million in windfall profits from shares acquired at the depressed offering price due to the alleged misinformation [3]. - Cerevel's January 18, 2024, Proxy statement is claimed to have misled investors regarding the nature and timing of AbbVie's interest in the company [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant period have until June 3, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [4]. Group 4: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5].

Core Viewpoint - AbbVie Inc. (ABBV) is experiencing an upward trend in its stock price, gaining over 12% in the past week, but is now considered overbought, which may attract sellers and pressure the stock lower [1][2]. Group 1: Stock Performance - AbbVie has been trading higher, with a notable increase of more than 12% in the past week [1]. - The stock is currently classified as overbought, indicating that it has moved above its normal trading range [1]. Group 2: Market Dynamics - The concept of reversion to the mean suggests that an overbought stock like AbbVie may experience a downward movement, prompting some traders to sell in anticipation of this trend [2]. - The Relative Strength Index (RSI) is highlighted as a popular momentum indicator, with a default time period of 14 days, which currently shows neutral momentum for AbbVie [2][4]. Group 3: Technical Analysis - A 14-day RSI indicates that today's price is roughly the same as it was two weeks ago, not reflecting the recent rally [4]. - Adjusting the RSI time period from 14 to 5 days reveals that AbbVie shares are very overbought, suggesting a potential pause or end to the rally [5].